You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

IBS: Improving Diagnosis, Serotonin Signaling, and Implications for Treatment

  • Authors: Authors: Lucinda Harris, MD; Lin Chang, MD
  • THIS ACTIVITY HAS EXPIRED
Start Activity


Target Audience and Goal Statement

This activity is intended for the physician and other healthcare professionals specializing in the care of the patient with irritable bowel syndrome (IBS).

The goal of this activity is to familiarize the clinician with the clinical relevance of serotonergic signaling in the gut, mechanisms of visceral hypersensitivity, and the role of pathophysiology in understanding symptom presentation in IBS, all with a view toward implications for disease management.

Upon completion of this activity, participants will be able to:

  1. Review issues important to the appropriate diagnostic evaluation of the patient suspected of having IBS.
  2. Explore the relationship between the pathophysiology of IBS and mechanisms of serotonin signaling.
  3. Evaluate the utility/role of serotonergic interventions in the management of patients with IBS.


Author(s)

  • Lin Chang, MD

    Associate Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California; Co-Director, Center for Neurovisceral Sciences & Women's Health at UCLA, Los Angeles, California

    Disclosures

    Disclosure: Dr. Chang disclosed that she has received grants for clinical research from, has served as an advisor or consultant for, and is on the Speakers' Bureau for Novartis and Glaxo SmithKline. She has received grants for clinical research from and has served as an advisor or consultant for Forest Laboratories, Solvay, and AstraZeneca. Dr. Chang reported that she discusses the investigational products cilansetron, prucalopride, renzapride, paroxetine, fluoxetine, venlafaxine, and desipramine.

  • Lucinda A. Harris, MS, MD

    Associate Professor of Clinical Medicine, Weill Medical College of Cornell University; Associate Attending, The New York Presbyterian Hospital, New York, NY

    Disclosures

    Disclosure: Dr. Harris disclosed that she is on the Speakers' Bureau for Novartis , Janssen, GlaxoSmithKline, TAP Pharmaceuticals, and Wyeth. She has received grants for clinical research from Solvay, Forest Laboratories, and Glaxo SmithKline. She has served as an advisor or consultant for Solvay, and GlaxoSmithKline. Dr. Harris reported that she discusses the investigational products cilansetron, prucalopride, renzapride, paroxetine, fluoxetine, venlafaxine, and desipramine.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

IBS: Improving Diagnosis, Serotonin Signaling, and Implications for Treatment

processing....

Pharmacologic Treatment of IBS: Context

Although there are a number of traditional and novel therapies for IBS, for contextual purposes, the scope of this review will be limited to discussion of the serotonergic agents. Excellent systematic reviews of IBS clinical treatment trials can be read for a more comprehensive discussion of available therapeutic agents.[47,48] As reiterated in these reviews, many of the traditional therapies are used to treat specific IBS symptoms because they have not been shown to significantly relieve global symptoms, which would improve an overall sense of well-being. However, the discovery of the serotonergic molecular targets has led to the development of novel medications and reevaluation of relatively older pharmacologic agents that also act on the serotonin system. In well-designed, multicenter clinical trials, these novel serotonergic agents have been shown to be effective in treating global symptoms in patients with IBS compared with placebo.